Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2.
Adult
Antibodies, Viral
/ blood
Betacoronavirus
/ immunology
COVID-19
Case-Control Studies
Coronavirus Infections
/ diagnosis
Female
Humans
Immunoassay
/ methods
Immunoglobulin G
/ blood
Immunoglobulin M
/ blood
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ diagnosis
Point-of-Care Systems
Retrospective Studies
SARS-CoV-2
Sensitivity and Specificity
Serologic Tests
/ methods
Virus Shedding
Antibody response
COVID-19 pandemic
Immunochromatographic assay
Lateral flow method
Rapid test
Journal
The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
09
05
2020
revised:
30
05
2020
accepted:
01
06
2020
pubmed:
20
6
2020
medline:
29
8
2020
entrez:
20
6
2020
Statut:
ppublish
Résumé
We aimed to evaluate the role of rapid serological tests in the management of coronavirus disease 2019 (COVID-19) patients. This retrospective study enrolled 16 real-time reverse transcription polymerase chain reaction-confirmed symptomatic patients with COVID-19 and 58 COVID-19 negative patients at a medical center in Taiwan over a 3-month period. Serial serum samples were collected and tested for antibody response using four point-of-care (POC) lateral flow immunoassays (LFIA) (ALLTEST 2019-nCoV IgG/IgM Rapid Test, Dynamiker 2019-nCoV IgG/IgM Rapid Test, ASK COVID-19 IgG/IgM Rapid Test, and Wondfo SARS-CoV-2 Antibody Test). Time-dependent detection sensitivity and timeliness of seroconversion were determined and compared between the four POC rapid tests. The overall sensitivity and specificity of the four tests for detecting anti-SARS-CoV-2 antibodies after 3 weeks of symptom onset were 100% and 100%, respectively. There was no significant difference between the rapid tests used for detection of IgM and IgG separately and those used for detection of combined total antibody (mainly IgM/IgG). There was no significant difference between the four POC rapid tests in terms of time required for determining seroconversion of COVID-19. Patients with COVID-19 with pneumonia demonstrated shorter seroconversion time than those without pneumonia. Though the POC antibody rapid tests based on LFIA showed reliable performance in the detection of SARS-CoV-2-specific antibodies, the results of these tests should be interpreted and applied appropriately in the context of antibody dynamic of COVID-19 infection. COVID-19 patients complicated with pneumonia exhibited earlier anti-SARS-CoV-2 antibody response than COVID-19 patients without pneumonia.
Identifiants
pubmed: 32553841
pii: S0163-4453(20)30404-7
doi: 10.1016/j.jinf.2020.06.023
pmc: PMC7295501
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
435-442Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no conflict of interest.
Références
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Trends Mol Med. 2002 Jun;8(6):257-60
pubmed: 12067606
Lancet. 2020 Mar 21;395(10228):949-950
pubmed: 32151324
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830861
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32430429
J Med Virol. 2020 Sep;92(9):1518-1524
pubmed: 32104917
J Microbiol Immunol Infect. 2020 Jun;53(3):386-388
pubmed: 32299784
JAMA. 2020 Jun 9;323(22):2249-2251
pubmed: 32374370
J Infect. 2020 Aug;81(2):318-356
pubmed: 32283147
J Microbiol Immunol Infect. 2020 Jun;53(3):485-487
pubmed: 32198005
Emerg Infect Dis. 2003 Sep;9(9):1163-7
pubmed: 14519257
Nat Rev Microbiol. 2017 Mar;15(3):161-168
pubmed: 28134265
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Virol. 2012 Apr;86(7):3890-904
pubmed: 22278230
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
J Microbiol Immunol Infect. 2020 Jun;53(3):413-418
pubmed: 32224117
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
J Infect. 2020 Aug;81(2):e55-e58
pubmed: 32335168